Investors and analysts reacted immediately to Novo's revelation. The price of Novo's common stock declined dramatically. From ...

NEW YORK, NY / ACCESS Newswire / February 6, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about ...

Trademark prosecution data reveals how the rival healthcare companies are ensuring exclusivity internationally for their ...

Sales of Lilly's top-selling product, the diabetes treatment Mounjaro, jumped 60% to $3.53 billion in the final quarter of ...

On an adjusted basis, the U.S. drugmaker expects to earn between $22.50 and $24.00 per share in 2025. Analysts were expecting ...